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 Diagnosis and treatment of disease in its early stages is often the key to 
success. The 20th century saw impressive applications of engineering technology in early 
stage diagnosis, as well as the application of such technology in other fields of medicine. 
Taking advantage of the new development in the field of material science and synthetic 
techniques for developing nanoparticles, the field of nanomedicine has emerged and one 
of its goals is to diagnose early stage disease when it is still at molecular level. By 
allowing for the non-invasive and quantitative detection of disease biomarkers, 
nanoparticles provides substantial improvements in both specificity and sensitivity of 
diagnostic imaging [1-4].  
The unique properties of nanoparticles provide a new platform in molecular 
imaging for early detection of diseases such as cancer and atherosclerosis. One class of 
nanoparticles are superparamagnetic iron oxide nanoparticles (SPIOs), which consist of 
an iron oxide core with a PEG coating that can be functionalized with a targeting ligand 
and a radiotracer. The targeting agent can be selected to recognize a disease biomarker 
therefore, enhancing the contrast between malignant and benign tissue. The radiotracer 
will enable imaging with PET (positron emission tomography) which has the highest 
sensitivity among all imaging modalities [5]. The large surface area of the SPIO enabled 
labeling with high specific activity leading to significant increase in sensitivity of the 
detection. SPIOs can be loaded with reporter molecules such as radionuclide and 
targeting proteins and peptides. In our lab, we have developed a new method for 
synthesizing SPIOs with tight control over their diameter and surface chemistry [6].  
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Due to the continuous exposure of atherogenic factors, molecular events occurring at the 
endothelium contribute significantly to the development of atherosclerotic plaques. In 
particular, endothelial expression of adhesion molecules such as vascular cell adhesion 
molecule (VCAM1), which is involved in leukocyte recruitment, plays a critical role in 
the earliest stages of atherogenesis. Detection of molecular markers of early-stage 
atherosclerotic plaques such as VCAM-1 requires high sensitivity targeting.  Although 
methods based on various medical imaging modalities, including ultrasound, X-ray 
computed tomography (CT) and MRI, have been developed and utilized for detecting 
plaque volume and constituents and for visualizing the vessel lumen and the vessel wall, 
PET imaging is the most sensitive human molecular imaging modality for plaque 
detection, since it can produce whole body images for functional and molecular 
information.  Therefore, emphasis in our in vivo imaging studies will be placed on 
developing nanoparticle-based contrast agents for PET imaging [7, 8]. Further, there are 
multitudes of PET tracers available to use for conjugation to many types of nano agents. 
With applications ranging from clinical and research in neurology and cardiology 
PET/MR allows for imaging in the main processes of cancer development: apoptosis 
resistance, angiogenesis, proliferation and metastasis [9]. 
This thesis established the ability to develop a functionalized PEG coating for the 
SPIOs which allows for labeling with both 
64
Cu and targeting ligand to recognize the 
disease biomarker. This will provide a platform for pre-clinical in vivo imaging of 





DUAL-MODALITY PET/MR CONTRAST AGENT 
Nanoparticles for PET/MR Imaging 
 
Nanoparticles used as a molecular imaging tool with extensive multifunctionality 
and flexibility provide platforms for targeting the specific disease biomarkers and 
integration of imaging modalities. One such molecular imaging tool is super 
paramagnetic iron oxide nanoparticles, SPIOs, widely used as Magnetic Resonance (MR) 
contrast agent. SPIOs can be labeled with 
64
Cu to investigate their potential for multi 
modal positron emission tomography (PET) MR imaging. Dual modality PET MR SPIO 
contrast agent can be synthesized to image diseases such as cancer and atherosclerosis. 
Positron emission tomography (PET) imaging is now the standard clinical diagnostic 
modality for staging and restaging of cancer and is one of the few molecular imaging 
techniques approved by the FDA. The advantage is the non-invasive and early detection 
of disease at molecular lever before it has spread to late stages or in case of the 
atherosclerosis before the plaque has blocked the vessel [10, 11].  
Positron Emission Tomography (PET) was created in 1970s to combine early 
biochemical assessment of pathology with the precise localization through the use of 
nuclear medicine and computerized image reconstruction. In this technique a biologically 
active chemical compound is labeled with a radioactive isotope that decays by emitting a 
positron. The positron then travels a small distance before combining with an electron 
and emitting two gamma photons [19]. This technology has a very high sensitivity 
compared to other image modalities and PET images can be interpreted to provide 
regional assessment of biochemical processes. The lack of anatomical information was 
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solved by combining PET with high resolution anatomical imaging like Computed 
Tomography (CT) in the late 1990s [20]. However, increased use of the CT which is 
associated with ionizing radiation has led to concern among the radiology community 
(radiologists, medical physicists, and manufacturers) [21]. Combination of PET and MR 
is an attractive option since MR provides high anatomical resolution without the harmful 
effects of ionizing radiation and much effort has been invested in developing a PET/MR 
diagnostic imaging system [22, 23]. To better visualize the existence of malignancy with 
this system, a dual modality contrast agent such as radio-labeled SPIO is developed. Dual 
modality PET MR SPIO contrast agent can be synthesized to image diseases such as 
cancer and atherosclerosis. The advantage is the non-invasive and early detection of 
disease at molecular lever before it has spread to late stages or in case of the 
atherosclerosis before the plaque has blocked the vessel. There are however many 
challenges in the development of the multi-modal PET MR contrast agent. The 
radionuclide used for PET imaging has a limited half-life; also chemical conjugation 
methodologies must be developed to ensure that the particle stays intact after it is 
exposed to the harsh environment inside the body [24]. 
The unique decay properties of 
64
Cu make it useful as a radiotracer for PET. It has 
a longer half life (12.701 ± 0.002 hours) compared to FDA approved 
18
F and decays by 
17.86%  positron emission, 39.0% by beta decay, 43.075% by electron capture and 
0.475% gamma radiation/internal conversion. The half-life of 12.7 hours makes 
64
Cu 
appropriate for radiosynthesis and allows for imaging 24 hrs post injection. The beta- 
decay makes it appropriate for radiotherapy as well. Another main advantage is the low 
radiation burden and the wide application in clinical investigations. It can also be 
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produced in high yield and high specific activity which is required for in-vivo PET 
imaging [25]. 
Figure 1 shows the schematic of the SPIO nanoparticle with the Fe3O4 core, and 
functionalized PEG coating that allows for conjugation of targeting ligands, NIRF dyes, 




Figure 2 shows the schematic of the synthesis of 
64
Cu-VINP-SPIO. Iron cores 
were coated with DSPE-PEG2k-methoxy, DSPE-PEG-maleimide, and lipid-PEG-BAT to 
prepare them for dual PET/MR imaging. Macrocyclic ligand BAT allows for 
radiolabeling by chelating of copper 64. The maleimide coating of the nanoparticles 
provide a site for attachment of VINP peptide.  
Figure 2 shows the major steps toward the synthesis of 
64
Cu-VINP-SPIOs. 
Uniform Fe3O4 iron cores (1) were first pegylated with lipid-PEG-BAT, DSPE-PEG-
 
 
Figure 1: A schematic of SPIO nanoparticle as a dual-modality image contrast agent.   
Fe3O4 core is used as a T2 contrast agent , 64Cu is the positron emitter used for PET 





methoxy, and DSPE-PEG-maleimide (2), which was subjected to VINP peptide 
conjugation (3). 
64
Cu labeling was performed in the last step to generate 
64
Cu-BAT-




 This simplified synthesis scheme has a great advantage over previously reported 
schemes. With this method, there is no need for post conjugation of the chelator for 
64
Cu. 
This leads to higher nanoparticle stability and radioactive yield. There is also a much 
 
 
Figure 2: A schematic of the synthesis of 
64
Cu-VINP-SPIOs.  
Uniform Fe3O4 core (1) nanoparticles were first pegylated with lipid-PEG-BAT, DSPE-
PEG-methoxy, and DSPE-PEG-maleimide (2), which was subjected to VINP peptide 
conjugation (3). 
64







improved control over the amount of chelators that can be incorporated into the SPIO 
nanoparticles. This allows us to modulate the radioactive yield depending on the 
application.   
SPIO Characterization 
 
The number of VCAM targeting VINP peptides per nanoparticle was measured 
by using an Abcam maleimide quantification assay on maleimide activated nanoparticles 
before and after peptide conjugation. The difference in thiol concentration between Mal-
BAT-SPIO and VINP-BAT-SPIO was used to calculate the average number of VINP 
peptides conjugated to Mal-BAT-SPIO.  
The hydrodynamic diameter and surface potential of Mal-BAT-SPIO and VINP-
BAT-SPIO was measured by dynamic light scattering (DLS). DLS measurements were 
performed using a Malvern Zetasizer Nano ZS. Samples were measured in triplicate 
(with 5 runs each) at 25 °C and data are reported as the average ξ potential (mV).  
Iron concentration of Mal-BAT-SPIO and VINP-BAT-SPIO solutions was determined 






Cu Radiolabeling, Characterization and Serum Stability 
 
Radiolabeling of BAT-VINP-SPIOs was obtained by incubation with 
64
Cu at 37 
°C for 1 hr in 0.1 M ammonium acetate buffer, pH 5.5. In this study 
64
Cu-VINP-SPIOs 
was labeled to a specific activity of 45 μCi/μg. Nonspecifically bound 
64
Cu was removed 





Cu-VINP-SPIOs using filter centrifugation. Quality control was 







Figure 3: Characterization of SPIOs using TEM, DLS diameter and zeta potential measurements. 
A TEM image of 6nm 
64
Cu-BAT-VINP-SPIO and  14nm 
64
Cu-BAT-VINP-SPIO is shown on the top. DLS 





 A small amount of the of the 
64
Cu SPIO solution was applied to an ITLC-SG plate 
(Pall Corporation, East Hills, NY) and developed using a 1:1 mixture (v/v) of 10% (w/v) 
ammonium acetate and methanol (Rf = 0 for 
64




Cu-acetate). The TLC plate was then measured using a Rita Star (Raytest, 
Straubenhardt, Germany). 
Radiochemical purity (RCP) of 
64
Cu SPIO was evaluated by radio-fast protein 
liquid chromatography (radio-FPLC) using an Amersham Biosciences ÄKTA FLPC 
system (GE Healthcare, Piscataway, NJ) equipped with a UV detector (280nm) and fitted 
with an in-line Flow-Count radioisotope detector (Bioscan, Poway, California). A 100 μL 
sample of dilute 
64
Cu-SPIO was applied to a Superose 12 gel filtration column (GE 
Healthcare, Piscataway, NJ) and eluted with 20 mM HEPES and 150 mM NaCl (pH 7.3) 
at a flow rate of 0.8 mL/min. The RCP of 
64
Cu –SPIO was found to be > 98%. The 
nanoparticle solution was then diluted in PBS (pH 7.4) to obtain doses (10-100 μCi) 





Figure 4: Characterization of 
64
Cu radiolabeled SPIOs using radio-TLC.  
64
Cu-SPIOs (90%) are shown in the green peak and the free 
64












The number of BAT groups available to chelate the Cu was estimated by adding 
100 µg of the nanoparticles to a known excess of “hot plus cold” Cu-acetate. After 1 hr 
incubation at 37 
o
C, a 10mM EDTA was added and the resulting solution was incubated 
for 5 min at 37 
o
C.  Aliquotes were then analyzed by radio-TLC. The percent labeling 
yield increased as the amount of cold copper decreased as shown in Figure 4. The number 
of BAT chelators attached to the SPIO was determined from the following equation: 
 (        )  
 (      )                    ( )
   
 




Serum stability of 
64
Cu–SPIO was measured by radio-TLC and radio-FPLC 
analysis after 0, 1, 3, and 24 hr incubation in mouse serum at 37°C with constant shaking. 
A 100 ul volume of SPIO solutions with 100 ul of mouse serum at 37
o
C up to 24 hr. A 
small aliquots was injected to the radioFPLC and % bound activity was calculated for 
each time point.  
 
Figure 5: Titration experiment to determine the number of BAT chelators per particle. 
 
































As shown in Figure 6, serum stability showed that both VCAM targeted 
64
Cu-
SPIOs and non- targeted 
64
Cu-SPIOs are stable in mouse serum up to 24 hr and less than 
10% dissociation of 
64
Cu or degradation of SPIOs was observed.   
Discussion and Conclusion 
 
 We developed a simplified method for developing radiolabeled targeted SPIOs. 
This method takes advantage of the chelator BAT that is conjugated to the PEG before 
the coating process begins. This conjugation eliminated a need for post conjugation of the 
chelator DOTA and significantly improved the radiolabeling yield. It also allowed for the 
incorporation of DSPE-PEG2k-maleimide and conjugation of the targeting peptide. 
Chelator BAT which is a derivative of TETA has higher affinity for 
64
Cu compared to 
DOTA. This leads to higher in vivo stability and overall particle stability as is shown in 
the serum stability results. We characterized the particle size, radiochemical yield and 
serum stability to make sure it is suitable for in vivo imaging applications. Although the 
radiolabeling yield was very high (90%) with only 10% free 
64
Cu-EDTA, we performed 
Figure 6: Mouse serum stability of Targeted and non-targeted 
64
Cu-SPIOs analyzed using 































four rounds of filter centrifugation to wash and purify the SPIOs from free 
64
Cu and 
reaction buffer. The final sample had a radiochemical purity of higher than 99% and was 
dissolved in PBS for further in vitro and in vivo studies. SPIOs had a very uniform size 
distribution after coating and conjugation as shown in TEM and DLS results. The 
particles uniform size distribution and functionalized PEG coating allows for improved 
characteristics over the existing iron oxide nanoparticles. A titration experiment was 
performed with a mixture of hot and cold copper to estimate the number of BAT 
chelators. On average there were 15 chelators per particle. A specific peptide sequence 
which is shown to be specific for VCAM1, VINP (VHPKQHRGGSYGC) was 
conjugated to the maleimide group to make 
64
Cu-VINP-SPIOs. We explored the use of 
anti-VCAM antibody but found the use of VINP peptide beneficial in comparison. To 
confirm specificity, we also tested a modified version of the SPIO conjugated to scramble 
peptide (PRHKVQHGGSYGC). The peptide is smaller than the antibody which leads to 
longer circulation half-life. The conjugation of the peptide is easier when compared to 
antibody and it is cost efficient. This peptide targeted particle was used in the 
biodistribution and PET imaging studies of inflammation. Although there are challenges 
in the efficient synthesis of SPIOs, they have a great potential in being used in pre-
clinical imaging. 
 The dual modality of SPIOs allows for imaging with both PET and MRI. PET 
imaging provides high sensitivity while MRI has very high soft tissue contrast. Although 
PET and MRI systems are not combined and we will perform our studies on separate 
systems, we hope that in the future this nanoparticle be translated to clinic for use as a 
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EFFECT OF SIZE ON NANOPARTICLE PHARMACOKINETICS 
AND BIODISTRIBUTION 
In the past 30 years, nanotechnology has become a promising strategy for 
diagnostic, imaging, and therapeutic applications [1]. Altering a nanoparticle’s size, 
shape, and surface chemistry allows nanoparticles to be tailored to different functions [2, 
3, 4]. Nanoparticles are rendered useless, however, if they do not first reach the targeted 
tissue. Rapid clearance of nanoparticles from the human body by the mononuclear 
phagocyte system (MPS) and reticuloendothelial system (RES) is one of the biggest 
obstacles to ensuring that nanoparticles reach their target [1, 5]. Alterations of 
nanoparticle size attempt to modulate the pharmacokinetics and temporarily prevent 
clearance from the blood [5, 6]. Successful evasion of the RES for certain time points 
post-injection can be observed by measuring blood circulation half-life and examining 
the biodistribution of nanoparticles in the blood, the RES organs, and the targeted tissue 
[6]. Currently, nano-bio interactions are being studied so that design specifications may 
be established to aid in the development of nanodevices with properties that allow them 
to reach the targeted tissue [1]. 
When designing nanoparticles, the specific functionality must be considered. For 
example, nanoscale therapeutics for tumors relies on cellular uptake and tumor 
permeability. Both of these factors depend on a nanoparticle’s size [1, 7, 8]. Likewise, 
nanoparticles used to enhance an imaging modality have size-dependent properties. The 
size of the nanoparticle will affect uptake by targeted cells, as well as both positive and 
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negative contrast in an image [9, 10, 11]. The specific location and type of targeted tissue 
will also impact the ideal size of a nanoparticle [12]. 
Developing a complete understanding of the effects that nanoparticle size has on 
various functionalities is crucial. As these effects are discovered, general rules can 
emerge that can be applied to models, making them more accurate [13]. Models can 
streamline future nanoparticle construction and provided a quantitative relationship 
between nanoparticle size and biodistribution [13]. The current state of knowledge 
regarding the in vitro and in vivo effects of nanoparticle size, specifically in therapeutic 
and diagnostic applications, is summarized in this review.  
Trends in vitro 
 
There is a growing interest in investigating the in vitro effects of nanoparticle size 
[13]. Numerous in vitro studies have been conducted, which involve different cell types, 
probes with various core materials, surface charges, and tested size ranges [4, 5, 9, 15, 16, 
30]. These studies show size-dependent trends in cellular uptake and active targeting. In 
this review, an analysis of the specific in vitro trends will be discussed, with some high 
impact studies highlighted in Table 1. 
Cellular Uptake 
 
Nanoparticle shape, core composition, and size are strong determinants of cellular 
uptake [1]. Nanoparticle shape, whether spherical, cubic, rod-like, or worm-like, 
influences cellular uptake [18, 17]. In a comparison between cubic, spherical, and rod-
like gold nanoparticles, spherical particles showed the highest uptake in terms of weight, 
on the other hand rod-like nanoparticles showed the highest uptake in terms of quantity 
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[18]. DOX-loaded polymeric nanoparticles showed a similar trend, with a higher cellular 
uptake in MCF-7 cells observed for rod-like and worm-like nanoparticles than spherical 
nanoparticles [17].  
Nanoparticle size also impacts cellular uptake due to its influence on the enthalpic 
and entropic properties that govern the adhesion strength between nanoparticles and 
cellular receptors [3]. Zhang et al. developed a thermodynamic model that showed 
optimal cellular uptake when a ligand-coated nanoparticle is 50 nm in diameter [14]. In 
experimental studies with HeLa cells, a spherical nanoparticle with a 50 nm diameter 
showed the highest cellular uptake [15]. In addition, a targeting study using gold 
nanoparticles reported the highest cellular uptake with 40-50 nm diameter gold 
nanoparticles in SKBR-3 cells [16]. The same trend was observed when the core was 
changed from gold to silver [16]. 
As shown in an illustration in Figure 7, size-dependent uptake is likely related to 
the membrane-wrapping process that a nanoparticle undergoes during endocytosis [1, 
14].  Due to a ligand shortage, small nanoparticles must bind to receptors in close 
proximity to drive the membrane-wrapping process. The enthalpic limit occurs at a 
nanoparticle size of about 30 nm, meaning particles smaller than this limit will not drive 
the membrane-wrapping process effectively [19]. Small nanoparticles also tend to 
dissociate from the cellular receptors before endocytosis can occur [16]. In contrast, large 
nanoparticles drive the membrane-wrapping process by binding to many receptors; 
however, a nanoparticle above 60 nm results in a receptor shortage, which decreases 
uptake because of the increasing entropic penalty [19]. Although the exact optimal 
diameter varies between applications, a nanoparticle between 30 and 60 nm in diameter 
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can recruit and bind to enough cellular receptors to drive the membrane-wrapping process 
without a receptor shortage affecting endocytosis [14, 19]. Most in vitro studies show a 
maximum cellular uptake within the 30-60 nm range, regardless of core composition or 
surface charge [5, 9, 15, 20]. 
 
Other parameters affecting cellular uptake are surface charge and cell type. Liu et 
al. conducted a study comparing the uptake of a range of gold nanoparticle sizes with 
both positive and negative surface charges. In phagocytic cells, positively-charged 
nanoparticles showed higher uptake for each size [5]. Interestingly, the positively-
charged nanoparticles showed the greatest uptake with a 58 nm diameter particle, but the 
negatively-charged particles showed the greatest uptake with a 40 nm diameter particle 
 
Figure 7: A schematic depicting the effect of nanoparticle size on the membrane wrapping process. 
Nanoparticles greater than 60 nm in diameter driving the membrane-wrapping process by binding to a 
large number of receptors but limiting the binding of other nanoparticles (A). Nanoparticles less than 30 
nm in diameter attaching to some membrane receptors but failing to drive the membrane-wrapping 
process unless many bind to receptors in close proximity (B). Nanoparticles between 30 nm and 60 nm 




[5]. Likewise, nonphagocytic cells showed a significant increase in the uptake of 
positively-charged particles compared to negatively-charged particles. Again, the 
maximum uptake of negatively-charged particles was seen with a 40 nm diameter, while 
the maximum uptake of positively-charged nanoparticles was seen in particles with a 58 
nm diameter [5]. Further comparison shows no definite size-dependent trend in the 
uptake of positively-charged particles, but negatively-charged particles showed a trend of 
higher uptake at 40 nm [5]. Drug-loaded polymeric nanoparticles were tested in a similar 
manner, and showed similar results regarding the effects of surface charge. The 
macrophage cells showed increased uptake with increased nanoparticle size, while non-
phagocytic cells showed increased uptake with decreased nanoparticle size [21].  Yu et 
al. explored the size-dependent uptake of macrophage cells alone. Ultrasmall 
superparamagnetic iron oxide (uSPIOs) nanoparticles surrounded by PEG-
poly(propylene sulfide) (PEG-PPS) were synthesized to be 30 nm, 40 nm, or 100 nm in 
diameter. As previously reported with polymeric nanoparticles, increased uSPIO size 
correlated with increased uptake by macrophage cells [22]. However, an in vitro study 
with macrophage cells resulted in the highest uptake at a diameter of 37 nm, which was 
not the largest size tested [9]. Currently, it is unclear if size-dependent uptake follows a 
different trend in macrophage cells than in nonphagocytic cells [5, 21, 22]. To develop a 
toolbox for designing nanoparticles that avoid the MPS, further studies are required to 







Nanoparticles are frequently coated with polyethylene glycol (PEG) to avoid the 
RES system and increase blood circulation half-life. The PEG coating makes the 
nanoparticle more hydrophilic and neutral, allowing them to bypass the immune system 
more easily; however, PEG poorly affects the cellular uptake and drug release [6, 23, 24]. 
Adding targeting ligands to the surface of a PEG-coated nanoparticle increases cellular 
uptake, helping to mitigate the uptake loss due to the initial PEG coating. The addition of 
targeting moieties improves the delivery process through active targeting of 
overexpressed antigens [25]. Surface ligands that bind to cellular receptors result in 
receptor-mediated uptake. A critical number of receptor-ligand interactions must occur to 
produce enough thermodynamic energy to overcome the resistive forces such as 
membrane elasticity and thermal fluctuations [26].  It is important to note that active 
targeting has drawbacks. Conjugating surface ligands to nanoparticles increases 
macrophage recognition and allows faster clearance compared to the non-targeted 
nanoparticles [24]. Active targeting can also create a binding site barrier effect, limiting 
nanoparticle penetration into the targeted tissue [27]. The in vivo drawbacks make it 
unclear if active targeting actually assists in the delivery process [27].  
A possible solution to this problem is masking target ligands with a cleavable 
PEG-lipid conjugate. Masking the targeting ligands ensures ample circulation time while 
still utilizing active targeting [28]. In one study, nanoparticles targeted with folate 
receptor-targeted (FRT) liposomes were masked with a cysteine-cleavable 1,2-distearoyl-
sn-glycero-3-phosphoethanolamine (DSP) - PEG coating were incubated with 9L glioma 
cells. Significant uptake was observed only in cells treated with cysteine [28]. Further in 
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vivo investigation revealed that the FRT masked nanoparticles did specifically target 
tumor cells after a cysteine injection and showed higher tumor cell uptake rates than 
nanoparticles without targeting liposomes, indicating the masking method is a promising 
solution to difficulties with active targeting [28].   
To optimize active targeting via ligand density, Elias et al. conducted a study with 
HER2-targeted superparamagnetic iron oxide nanoparticles (SPIOs) on HER2/neu-
positive (T6-17) cells. SPIOs were conjugated to HER2-affibodies previously ligated to 
an azido-fluorescent peptide (AzFP) at varying concentrations. 26 nm and 50 nm HER2-
AzFP conjugated SPIOs were synthesized with different ligand densities. Both showed 
that the highest degree of cellular uptake occurs at a concentration of 0.01 ligands/nm 
squared [3]. The ligand-receptor binding energy also affects cellular uptake. Zhang et al. 
found that a smaller optimal radius and higher maximal cellular uptake is achieved with a 
larger ligand-receptor binding energy. Within the common range of typical antibody-
antigen energies, the optimal radius can range from 25.4 nm to 30.2 nm [14]. 
Gold nanoparticles that are targeted to cancer cells show size-dependent cell binding  [8]. 
When comparing 15 nm, 30 nm, 90 nm, and 150 nm targeted gold nanoparticles, the 15 
nm diameter nanoparticles showed a 13-fold increase in cellular binding probability 
compared to the 150 nm diameter nanoparticles. However, 90 nm diameter cells showed 
optimal targeting in terms of gold mass per cell and surface area per cell [8]. While this 
indicates an optimal size range, additional studies should be conducted to evaluate the 
effects of size on targeting with differing parameters (e.g. varying cell lines, nanoparticle 




Trends in vivo 
 
While in vitro studies focus on individual aspects of the delivery process, in vivo 
studies shed light on the effects of nanoparticle size within the context of the body. Blood 
circulation half-life [6, 32, 33, 34], tumor permeability [7, 47, 34, 35], and biodistribution 
[4, 6, 32, 40] are all affected by the size of the nanoparticle. Table 2 provides a summary 
of several in vivo studies showing size-dependent trends. 
 
Blood Circulation Half-Life 
Once a foreign object enters a body, opsonization begins. Opsonin proteins attach 
to the foreign object and make it more visible to the mononuclear phagocytic system 
(MPS) [36]. A rapid MPS response results in the clearance of uncoated nanoparticles 
from the bloodstream within a few hours post-injection [4, 5, 32]. The rapid clearance of 
nanoparticles limited their use because nanoparticles do not have time to reach the 
targeted tissue [37]. Problems with avoiding the MPS have moved nanoparticles from the 
first generation of material design and biocompatibility to the second generation of 
stealth tactics and active targeting [1]. While some advances have increased circulation 
half-life (t1/2), such as PEG coating [2, 6, 23, 24], a closer look at the basic size of a 
nanoparticle shows significant, size-dependent changes in t1/2.  
Some specific size limitations are known. A nanoparticle with a diameter less 
than approximately 10 nm will be rapidly eliminated by the kidneys [6, 38]. The reason 
for this clearance can be found by looking at each component of the kidney’s filtration 
system. The kidney uses peritubular capillaries and renal corpuscles to filter the blood 
and produce urine. Within a renal corpuscle is the glomerulus, which has three layers 
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with varying pore sizes. The effective size cutoff of the overall structure is 10 nm [32]. 
The upper size limit of nanoparticles can vary based on the targeted cellular receptors 
[39], but a nanoparticle with a diameter greater than 200 nm will activate the complement 
system and be quickly removed from the blood stream, accumulating in the liver and 
spleen [2, 4, 33]. Moghimi et al. suggest a maximum size limit of 150 nm for spherical 
nanoparticles to avoid filtration in the spleen [40]. 
Further studies have narrowed the range of sizes and provided additional 
information about the effects of size on t1/2. In a comparison between 24 nm and 37 nm 
shell cross-linked nanoparticles, the smaller particle had a higher retention at 10 minutes 
and at 4 hours post-injection. At 1 hour post-injection, 50% of the smaller nanoparticles 
were found in circulation, compared to only 5% of the larger nanoparticles [37]. A study 
with gold nanoparticles systematically tested the effects of nanoparticle size and mPEG 
weight on t1/2. Five different nanoparticles, ranging from 17.72 nm to 86.73 nm, were 
each coated with mPEG 2 kDa, 5 kDa, and 10 kDa. The nanoparticles were injected into 
CD-1 mice, and t1/2 was calculated from blood samples drawn at specific time intervals. 
For each size, t1/2 increases as mPEG molecular weight increases. The greatest change is 
seen from mPEG 2 kDa to mPEG 5 kDa [34]. Between various core sizes, the smaller 
nanoparticles have a longer t1/2. For example, there was an 8-fold increase in t1/2 from the 
86 nm core to the 17 nm core with the same coating [34]. Therefore, decreasing 






As shown in Figure 8, each point represents a specific combination of 
characteristics that has been tested. Points are colored based on core material (yellow 
represents gold and purple represent quantum dots). The coating of the particle is shown 
by the lines surrounding each point. Black lines denote a PEG coating, with longer lines 
representing higher PEG molecular weight. Blue lines denote an S-PEG coating (silica 
shell with PEG5000 coating). Green lines denote a PIL coating. Within each point, 













In vivo biodistribution of nanoparticles changes depending on nanoparticle 
properties and interactions with the living system [13]. In particular, nanoparticle size 
affects the biodistribution of nanoparticles throughout the body [6, 32, 33]. Particles on 
the micrometer scale remain in the body much longer than particles on the nanometer 
scale [33]. In one in vivo mouse model, micrometer particles remained in the spleen and 
the site of injection for at least two weeks, while nanoparticles of the same material were 
almost completely cleared in the same time frame [33]. The largest accumulations of 
nanoparticles typically occur in the blood, liver, and spleen [6]. Generally, larger 
nanoparticles accumulate in the liver and spleen more rapidly. There is still debate as to 
whether the rapid accumulation is due to simple filtration or increased binding 
opportunities between the MPS cells and the nanoparticles [36]. Examining the variations 
in biodistribution for 24 nm and 37 nm diameter shell cross-linked nanoparticles, smaller 
particles show a lower accumulation in the liver at 10 minutes post injection and lower 
kidney uptake at 4 hours post injection. Uptake in the spleen showed no correlation to 
size [37]. The minimum size to escape renal filtration, 10 nm, is illustrated by examining 
the biodistribution of spherical gold nanoparticles with diameters of 10 nm, 50 nm, 100 
nm, and 250 nm at 24 hours post injection. The 50 nm diameter nanoparticle shows the 
lowest accumulation in both organs, but the 10 nm diameter nanoparticle shows the 
highest accumulation in the spleen and the liver [6]. In contrast, 15 nm, 50 nm, and 160 
nm gold nanoparticles functionalized with PEG show decreasing accumulation from 50 
nm to 15 nm [41].  
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Nanoparticle size impacts biodistribution within specific organs, as well as 
affecting the biodistribution throughout the body. The size-dependent distribution of 
nanoparticles is the result of various filters within organs or barriers between the organ 
and the surrounding fluid [4, 32]. For example, when nanoparticles from 20 nm to 100 
nm in diameter were injected into the kidney tissue, no correlation between the particle 
size and particle accumulation was found in the peritubular capillaries. However, there 
was a strong correlation between particle size and particle accumulation in the renal 
corpuscles. Nanoparticles 50 nm in diameter accumulated in all renal corpuscle cells with 
decreasing quantities as the nanoparticle diameter approaches the extremes of the tested 
range [32]. An example of a barrier’s impact can be found in a study that analyzed the 
effects of size when penetrating the blood-brain barrier. Nanoparticles between 25 nm 
and 500 nm were injected into rats; 3 hours post-injection, the biodistribution of 
nanoparticles in the brain tissue showed a strong correlation to nanoparticle size, with 25 
nm particles showing the greatest accumulation [4]. 
In order to determine the effects of nanoparticle size on biodistribution, 
nanoparticle properties and biodistribution model parameter must be quantified [13]. A 
possible future method of evaluating the biodistribution of nanoparticles is a 
physiologically based pharmacokinetic model (PBPK) [13, 42]. PBPK models are 
discussed in further detail in the modeling section. 
Pharmacokinetics of 6nm and 14nm SPIOs 
 
We performed blood pharmacokinetic studies with several variations of the 
64
Cu-
SPIOs to understand the effect of size and PEG density. Both 6 nm and 14 nm iron cores 
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were prepared with chelator BAT, with and without targeting peptide. In addition the 
ratio of PEG to iron was increased in the first step of coating to increase the PEG density.  
Particles were coated and characterized as shown in Figure 9. As shown, the size 
increased after coating with DSPE-PEG2k and the conjugation of VINP peptide. The 
surface charge was characterized with zeta potential. Sine maleimide group hydrolyzes, 
SPIOs have a negative charge before conjugation and the surface charge becomes more 







Figure 9: Characterization of 6 nm and 14 nm SPIOs using TEM, DLS diameter and zeta potential 
measurements.   
The sized increased after coating with DSPE-PEG2k and post conjugation of VINP peptide. The zeta 
potential became less negative after conjugation of VINP peptide. 
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All animal procedures were performed in compliance with guidelines set forth by 
the Emory University Institutional Animal Care and Use Committee. Pharmacokinetics 




Cu-VINP-SPIOs in C57BL/6 (n=5 per time point) mice. Blood samples were collected 
1min, 30min, 1 hour and 3 hour after injection in pre-weighed glass tubes. The weight of 
the blood was then measured and the amount of radioactivity was determined using a 
cobra counter.   
The half-life of the contrast agent was determined by curve fitting to the equation:  
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N0 referring to the initial amount of the contrast agent that decays; N(t) is the amount that 
still remains and has not yet decayed after a time t, T1/2 is the half-life time of the 
decaying contrast agent, fitted value b is connected to half-life time T1/2, db is the error of 
the fitted value b and dT1/2 is the error of the half life time. Figure 10 shows the result of 
pharmacokinetic studies. The results show that the addition of the targeting peptide 
significantly decreases the blood circulation half-life in both 6 nm and 14 nm SPIOs. As 
the core size increases, blood circulation half-life decreases. Also, the increase in PEG 
density coating of the SPIOs, increases the blood circulation half-life. Based on these 
results, we selected the 14 nm targeted 
64
Cu-SPIOs for tumor imaging and 6 nm 
64
Cu-











nanoparticles were administered via tail vein injection and accumulation in major organs 
was investigated. Groups of C57BL/6 mice (n=5 per time point) were sacrificed at 
15min, 1 hr, 3 hrs, and 24 hrs post injection and select organs were weighed and 
measured with Cobra Counter for activity. A standard dose was prepared and measured to 
calculate the percent injected dose per gram (%ID/g). Data are expressed as percent 
injected dose per gram (%ID/g). 
Biodistribution studies of 6 nm and 14 nm SPIOs 
 
Initially, 14 nm SPIOs were prepared with 5% DSPE-PEG-amine and conjugated 









several variation of size and PEG density.  
Higher PEG density increased the circulation half-life. The addition of targeting peptide 




performed and the results are shown in Figure 11. Blood circulation half-life is shorter as 








Cu-SPIOs. The particles were injected via retro-orbital injection 
in the following studies. As shown in Figure 12, %ID/g remains about 45% after 15 
minutes and slowly drops to about 30% 1 hr post injection. The blood circulation half-life 
was calculated by curve fitting and it was found to be 107.9 minutes. The RES uptake 




Figure 11: Biodistribution data of 14 nm Non-Targeted 
64



































To understand the effect of VINP targeting ligand on the nanoparticle 
biodistribution, the 6 nm 
64
Cu-VINP-SPIOs was injected to C57 mice and the 
biodistribution studies was performed similar to the non-targeted 6 nm. As shown in 
Figure 13, the blood circulation half-life is about 26% 15 minutes post injection. The 
dose drops to about 10% after an hour. The blood circulation half-life was estimated to be 
about 31 minutes. It is important to note the increase in the dose in kidneys as compared 
to the non-targeted SPIOs. This increase may be due to the uptake of particles by 




Figure 12: Biodistribution data of 6nm Non-Targeted 
64

































To understand the effect of size on biodistribution, 14 nm 
64
Cu-SPIOs were 
prepared. Figure 14 shows the biodistribution of 14 nm nanoparticles. The percentage 
remaining in the blood after 15 min was about 38% and declined over time to about 1% 
after 24 hours. The blood circulation half-life was calculated to be 84 minutes. The high 
uptake in the liver and spleen was expected. Compared to 6nm non-targeted SPIOs, the 





Figure 13: Biodistribution data of 6nm Targeted 
64



































As shown in Figure 15, biodistribution was repeated with 14 nm targeted 
64
Cu-
VINP-SPIOs in black C57 mice. As it was seen in the case of 6 nm, the blood circulation 
half-life was decreased by addition of peptide targeting ligand. Liver and spleen had a 
very high uptake. The uptake in the kidneys was increased by addition of peptide which 





Figure 14: Biodistribution data of 14nm Non-Targeted 
64


































Discussion and Conclusion 
 
The effect of nanoparticle size and PEG density was investigated in a series of in 
vivo experiments. Several variations of nanoparticles sizes (6 nm and 14 nm) with and 
without peptide targeting was prepared and injected to mice. The results show that 
nanoparticle circulation half-life can be increased by the increase in PEG density. The 
size of nanoparticle also affects circulation half-life. 6nm SPIOs had higher circulation 
half-life compared to 14 nm SPIOs. Also, addition of targeting ligand decreases the blood 
circulation half-life. The addition of targeting ligand, causes a corona of proteins to 
develop on the surface of the SPIOs making it easier to be recognized by the 
inflammatory cells especially macrophages. Therefore, this leads to shorter circulation 
half-life. However, the increase in PEG density causes a conformational change from 
mushroom to brush chain conformation and forms a think hydrophilic layer at the 
surface. The hydrophilic layer creates a steric barrier which prevents the adsorption of 
opsonins and lipoproteins to the surface of the SPIOs. The increased PEG density makes 
 
Figure 15: Biodistribution data of 14nm Targeted 
64































the SPIOs “invisible” to the reticulo-endothelial (RES) system, therefore prolonging their 
life time in the blood. This effect makes the SPIOs ideal vehicles for targeted imaging of 
tumor and plaque.  
We believe that the increase in the kidney dose that was observed with the 
addition of the targeting peptide is a result of binding and disassembly by components of 
the renal filtration barrier.  
The use of chelator BAT instead of DOTA causes the particle to clear the liver 
and spleen much faster. Based on these observations the 6 nm VINP-SPIOs with higher 
PEG density had the ideal blood circulation half-life for PET imaging of carotid ligation 
model. At the time, of these studies, we had determined that the focus of plaque imaging 
will be mainly on PET. Therefore, this particle with its long circulation half- life was 
mainly used to perform the imaging studies in the ligation model. The 14 nm CD105-
SPIOs with higher PEG density was prepared for tumor imaging studies. The increase in 
core size from 6 nm to 14 nm significantly improves the MRI contrast, therefore, they 
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According to American Heart Association atherosclerosis is a leading cause of 
death in the United States. About 40% of the adult US population is at immediate risk of 
developing a cardiovascular disease, such as arthrosclerosis. Arthrosclerosis is a 
progressive inflammatory disorder characterized by lesions or fatty streaks that develop 
into plaque deposits with a high risk of rupture and thrombosis. Current imaging 
techniques, such as serum C-reactive protein, provide minimal data analysis that limits 
the assessment of cardiovascular risk [1,2,3]. 
Atherosclerosis is a gradual process caused by a combination of endothelial cell 
dysfunction, lipid oxidation, and lipid accumulation. As a result of endothelial cell 
activation, inflammation begins. Endothelial cells begin to secret adhesion molecules 
such as VCAM1 which will draw monocytes and lymphocytes into the arterial wall. Once 
monocytes transverse the endothelial barrier, they will differentiate into macrophages, 
take up lipids and become foam cells. Plaques usually go undetected and eventually 
develop into more insidious, life threatening fat deposits which could instigate 
myocardial infarction or sudden cardiac death. If caught early on, these plaque deposits 
are reversible by mobilizing the lesions and removing them from the vessel wall by a 
process called reverse cholesterol transport which involves a sequence of enzyme-
mediated reactions[4- 6].  
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Once inflammation begins, the levels of C-reactive protein (CRP) which is a 
pentameric protein found in the blood plasma rises. Current techniques provide minimal 
data analysis that limits the assessment of cardiovascular risk. CRP is generally very low 
in healthy humans, however it significantly increases in patients with atherosclerosis even 
during the early stages of development [4- 6]. 
Figure 16 depicts the progression of atherosclerotic lesion and potential target for 
molecular imaging at each stage. 
 
VCAM1 Targeting  
 
Vascular adhesion molecule-1 (VCAM-1) is present in active endothelial cells, 
macrophages, and smooth muscle cells (SMCs) and is upregulated in atherosclerosis due 
to inflammation. It contributes to the recruitment and adhesion of lymphocytes to 
 
 
Figure 16: The progression of an atherosclerotic lesion [49]. 
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endothelial cells, forming plaque deposit [1, 7]. Currently, there are two developing 
techniques for detection: antibodies that bind to the surface of VCAM-1 expressing cells 
and expressing cells and specific peptides that are internalized by VCAM-1 expressing 
cells. Both methods have been studied extensively ex vivo as well as in vivo in order to 
determine which provides the most effective detection mechanism via magnetic 
resonance imaging (MRI). VINP linear peptide is shown to image atherosclerotic plaque 
in vivo. In this study, VINP peptide was conjugated to radio labeled SPIOs to image early 
stage plaque using PET and NIRF imaging, taking advantage of the nanoparticle long 
circulation half life and the superior sensitivity of PET imaging.   
VCAM-1 specific antibodies have been used in association with nanoparticles and 
microbubbles to detect arthrosclerosis for MR imaging in previously established ex vivo 
and in vivo studies[8,9]. Ex vivo studies have shown that anti-VCAM-1 antibodies can be 
used to detect plaque, however, a low target-to-background ratio makes it difficult to 
differentiate lesions in in vivo mice models [3,10]. This is confirmed by in vivo studies 
conducted on apolipoprotein E-/- (apoE-/-) mice with surface modified anti-VCAM1 
nanoparticles (VCAM-NPs) which were used to detect arthrosclerosis lesions via 
noninvasive MR imaging, however, at 1 hour most VCAM-NPs were still in circulation 
without clear signs of lesion receptor cell labeling. At 24 hours, accumulation of VCAM-
NPs was faintly detected within the lesions. These low intensity signals might have been 
due to the dissociation of the anti-VCAM1 antibodies from the target caused by the low 
bond formation rate of antibodies. In rapid, high-shear circulation through vessels, 
contact time might not be adequate for antibody attachment to lesions [3, 11] . In order to 
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intensify these signals and improve the target-to-background ratio of MR imaging, a new 
approach was taken, cell internalization of VCAM-1 specific peptides. 
A key advantage of VCAM-1 specific peptides is their capability to amplify 
signals through cellular internalization which improves uptake >12-fold in comparison to 
anti-VCAM-1 antibodies[1,12]. Ex vivo studies have been conducted with VCAM-1 
specific peptide sequence surface modified nanoparticles (VNPs) in order to determine 
the specificity of the particle for arthrosclerosis lesions in endothelial cells. An 11-fold 
higher accumulation was seen in activated endothelial cells compared to other VCAM-1 
expressing cells such as macrophages, thus suggesting that VNPs can be used to 
specifically target and detect arthrosclerosis[1,7]. Similar to the VCAM-NPs mice model, 
an in vivo study was conducted on apoE-/- mice via MRI to determine detection of 
lesions via peptide internalization. A change in signal intensity of MRI readings was 
detected with the accumulation of VNPs at arthrosclerosis regions which remained 
detectable for at least 24 hours [1, 7, 13]. This confirms that VNPs provide a more 
intensified detection of activated endothelial cells in comparison with VCAM-NPs in an 
in vivo model. VCAM-1 specific peptide sequences have also been used in ex vivo studies 
conducted on human carotid atheroma cells with a linear derivative of the cyclic peptide 
sequence used in Kelly et. al (VINP-28). This study suggests that VCAM-1 specific 
peptide sequences can be used in the future to detect arthrosclerosis in a clinical setting 
for humans. VINP-28 can also be used to tract the success of the arthrosclerosis treatment 
by detecting reductions in VCAM-1 expression as seen in apoE
-/-
 mice with an 
atherogenic diet that were statin-treated to reduce plaque buildup in vessel walls [1, 7]. 
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This noninvasive, progression methodology can be applied to a human model to track and 
analyze plaque development or depletion throughout the course of the disease. 
Both techniques for arthrosclerosis detection have proven effective in ex vivo 
models, however, the long term goal is to transfer this detection method from cell lines 
and animal models to a human compatible model. VCAM-1 specific cell internalizing 
peptides have proved to be the better prospective for transitioning this dual modality 
imaging model due to its higher target-to-background ratio in mice models as well as its 
ability to remain detectable for longer periods of time. The VCAM-1 specific peptide 
sequences have also been successfully tested in an ex vivo human cell model which 
broadens the possibility for this to be applied in vivo for humans as well as opens up its 




Novel imaging techniques have been used for the evaluation and quantification of 





FDG) imaging by PET and Ultrasmall superparamagnetic iron 
oxide (USPIO) nanoparticle-enhanced cardiac magnetic resonance (CMR) [15].  
In a dual modality PET/CT study of 932 cancer patients, 
18
FDG uptake was found 
to be a major predictor of future vascular events. In another study patients with cardio 
disease had a higher FDG uptake and a higher target-to-background ratio. There was a 
strong correlation between MMP-3 and MMP-9 and 
18
FDG uptake and It was determined 
that inflammation and calcification did not overlap in the same arteries.  
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In a study to determine treatment of atheroma with atorvastatin, USPIOs were 
used as a marker to identify macrophage infiltration. Since USPIOs are phagocytosed by 
macrophages with a sufficient quantity, they were detected by MRI. The use of the 
USPIOs is important because macrophage infiltration is one of the leading risk factors for 
plaque rupture.  
In a study by Weissleder, it was reported that VCAM-1 internalizing nanoparticle 
28 VINP-28 has the highest affinity for endothelial cells and undergoes cell 
internalization to increase contrast via MRI. There was a high plaque target-to-
background ratio for atherosclerosis. The VINP-28 was able to identified VCAM-1 
expressing cells in human carotid artheromata. The macrophages may have enhanced the 
contrast of atherosclerosis because there are more macrophages present at the plaque then 
endothelial cells that express VCAM-1. 
A second imaging technique is the contrast angiography that helps to visualize the 
plaque, however it is unable to view the entire arterial wall thus unable to identify 
changes in the disease such as alterations in wall thickness and plaque composition or 
volume. A third imaging technique is the intravascular ultrasound (IVUS) which is an 
invasive procedure that compensates for the angiography by allowing the diagnostician to 
view the progression of the plaque and the effects of drug therapy on the disease. An 
upcoming technique is computed tomography (CT) which is a minimally invasive 
procedure that accesses the wall thickening of arteries. Similar to the CT, high-resolution 
magnetic resonance imaging (MRI) can also be used as a noninvasive modality to 
monitor the plaque development, however both scans are very expensive to conduct on 
every potential patient [1,2,3,4, 16]. A more recent imaging technique is intravascular 
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optical coherence tomography (OCT) which is aimed at specific in vivo identification of 
vulnerable plaques. Although image artifacts inherent to the technique can lead to 
misclassification of pathology, OCT is the only technique able to detect eroded plaque 
thanks to its high spatial resolution [18].  




CuSPIO radiolabeling was optimized by changing the coating to a 
combination of 95% DSPE-PEG methoxy, 5% DSPE-PEG maleimide and 2% lipid-PEG-
BAT using the dual exchange solvent method. VCAM specific peptide was then 
conjugated to the SPIOs. In vitro studies with mouse endothelial cells revealed that the 
targeted SPIOs specifically target the VCAM1 on the surface of the cells about 5 fold 




Figure 17 shows the representative fluorescence images of immortalized mouse 
aortic endothelial cells (iMAECs) stained with DiI labeled VINP-SPIOs, Scramble-
SPIOs, or SPIOs after 1 hour incubation and subsequent washing with a 0 ng/mL and 100 
ng/mL of LPS for 6 hours.  
Phantom Studies 
 





analyzed using a 50 µCi sample on a Siemens invion microPET scanner. Radiolabeled 
nanoparticles were prepared in microcentrifuge tubes, placed in the scanner in an upright 




Figure 17: In vitro investigation of VINP-SPIOs with iMAECs. Scale bar = 10 µm 
Representative fluorescence images of immortalized mouse aortic endothelisal cells (iMAECs) 
stained with DiI labeled VINP-SPIOs, Scramble-SPIOs, or SPIOs after 1 hour incubation and 
subsequent washing with a 0 ng/mL and 100 ng/mL of LPS for 6 hours. (b) the bar graph shows 
the average ± standard deviation (n=3) for 6nm SPIOs. CTRL represents SPIOs without the 
targeting ligand. SCRAM repreents scrambled peptide SPIOs, VINP represents experimental 
SPIOs with VCAM-1 specific peptide. The p-values after performing t-tests that reached 





Carotid Ligation Model 
 
All animal studies were carried out by procedures approved by the Emory 
University Institutional Animal Care and Use Committee (IACUC). ApoE
-/-
 KO mice 
were obtained from Jackson Laboratories. All mice were fed a chow diet and water ad 
libitum. Male mice were ligated between 8 and 10 wk of age. Full ligation of LCA was 
carried out as previously described. Briefly, anesthesia was induced by inhaled 
isoflurane. Epilated area was disinfected with betadine, and a ventral midline incision (4–
5 mm) was made in the neck. LCA was exposed by blunt dissection. LCA was ligated 
while the RCA was left intact. The incision was then closed with monofilament sutures. 
Mice were monitored until recovery in a chamber on a heating pad following surgery. 
Buprenorphine was given after ligation for pain relief. Figure 19 shows the schematic of 













In vivo and Ex vivo imaging using DiR labeled SPIOs 
 
To optimize the imaging time, DiR labeled SPIOs were injected into ApoE
-/-
 KO 
mice and imaged with in vivo near infrared imager 1hr, 2 hr, 3 hr, 4 hr, 6 hr and 24 hr 






Figure 19:  Carotid ligation model and experimental set up. Full ligation surgery was performed on 
ApoE
-/-










Figure 20 shows Representative in vivo NIR imaging with  A) control ApoE
-/-
 KO 
mice and unconjugated SPIOs (n=2), B) control ApoE
-/-
 KO mice and VCAM peptide 
conjugated SPIOs (n=2) C) unconjugated SPIOs injected to carotid ligated ApoE
-/-
 KO 
mice 7 days post surgery (n=2) D) VCAM peptide conjugated SPIOs injected to carotid 
ligated APO KO mice (n=2). NIR images show the inflammation site with targeted 
SPIOs much better than the control SPIOs. (L-Ligation model, C-Control). To further 
quantify the targeting efficiency of VCAM-targeted SPIOs compared to control SPIOs, 
left and right carotids were excised and imaged at 24 hr time point. As shown in Figure 
21, ex vivo carotid artery analysis was performed with A) non conjugated control SPIOs 
on control mice (n=2), B) VCAM-SPIOs on control mice (n=2) and C) VCAM-SPIOs on 
ligation mice (n=2). (surgical ligation performed on left carotid, L-left, C-control). 









Figure 21: Ex vivo carotid artery analysis SPIOs. 
Ex vivo carotid artery analysis was performed with non-conjugated control SPIOs on control mice 
(n=2), VCAM-SPIOs on control mice (n=2) and VCAM-SPIOs on ligation mice (n=2). (Surgical 











MicroPET scans were performed using a microPET Focus 120 (Siemens Medical 
Solutions USA, Inc., Malvern, PA). C57/bl mice with carotid ligation were given tail vein 




Cu-scramble-SPIOs (0.1 mg Fe/kg body 
weight) in 100 μL PBS. The peptide sequence used as scramble is Anatomical 
information was obtained from CT scans (microCAT II, Siemens Medical Solutions 
USA, Inc., Malvern, PA) performed immediately after completion of microPET. Analysis 
of microPET images was accomplished using vendor software (ASIPro, Siemens Medical 
Solutions USA, Inc.) on decay-corrected images. Coregistration of microPET and 
microCT images was performed by Inveon Software package. Figure 22 shows the co-
registered microPET-microCT of C57bl mice with ligation on left carotid administered 
50 µCi of 
64
Cu-BAT-VINP-SPIO (10 mgFe/kg body weight, 100 µl injection volume). 
PET imaging of carotid ligation mouse model shows that VINP-
64
Cu-SPIOs accumulated 






The results of quantitative image analysis of PET signal due to SPIO 
accumulation in Left Carotid Artery (LCA, ligated) versus Right Carotid Artery (RCA, 
control) are shown in Figure 23. A region of interest was selected as the LCA and the 
standard uptake values (SUVs) were normalized by that at LCA to give the normalized 






Figure 22:  microPET/microCT images of inflammation in carotid ligation APO/E
-/- 
KO mice with 
targeted SPIOs.  
Co-registered microPET-microCT of C57bl mice with ligation on left carotid administered 50 µCi of 






PET/CT imaging of carotid ligation mouse model shows that VINP-
64
Cu-SPIOs 
accumulated more in the ligated left carotid compared to the right. Quantitative image 
analysis shows that the LCA over RCA ratio is about 2 fold higher when targeted SPIOs 
were tested in carotid ligation mode. Scramble-
64
Cu-SPIOs were used as a control in the 
ligation and control mice. The difference between the targeted SPIOs and other control 
groups were statistically significant (p<0.05). 
Discussion and Conclusion 
 
We have developed a multimodality nanoparticle-based contrast agent by 
integrating near-infrared dye DiR into the coating of 
64
Cu-SPIOs probes, and performed 





Figure 23: Quantitative image analysis of accumulation of SPIOs in Left Carotid Artery (LCA) 
versus Right Carotid Artery (RCA). 
A region of interest was selected as the LCA and the standard uptake values (SUVs) were normalized 


















Targeted SPIOs Ligated Mice
Scramble SPIOs Ligated Mice
Targeted SPIOs Control Mice



















imaging studies of inflammation with a carotid ligation mouse model. Specifically, 
SPIOs of 6 nm were coated with amphiphilic DSPE-PEG copolymer using a dual solvent 
exchange method. PEG molecules with amine and maleimide functional groups were 
incorporated in the coating for radiolabeling and targeting. These SPIOs were 
radiolabeled using 
64
Cu and conjugated with peptides (VINP) targeting VCAM-1. To 
determine the serum stability of 
64
Cu VINP-SPIOs, nanoparticles were incubated with 
mouse serum at 37
o
C and analyzed using radio-FPLC. The pharmacokinetics and 
biodistribution of 
64
Cu-SPIOs (non-targeted) and 
64
Cu-VINP-SPIOs were evaluated in 
vivo. Vessel wall inflammation was induced in murine carotid arteries through full 
ligation of left carotid artery (LCA). Carotid ligated mice were given tail vein injections 
with 50 μCi of 
64
Cu- 
VINP-SPIOs as targeted probes or 
64
Cu-scramble-SPIOs as control probes (0.1 
mg Fe/kg body weight) in 100 μL PBS.  PET/CT imaging was performed 4 hr post tail-
vein injection of 
64
Cu-VINP-SPIOs. Anatomical information was obtained from CT 
scans. PET imaging of carotid ligation mouse model showed that the 
64
Cu-VINP-SPIOs 
had a much higher accumulation more in the ligated left carotid compared to the right 
(control, no ligation). This accumulation could be due to mechanical restraining of the 
left carotid compared to right. But, the use of scramble conjugated SPIOs and non-
targeted SPIOs showed that mechanical narrowing of the artery increases the LCA to 
RCA ratio for scramble. But, this increase is more than 2 folds when using the VINP 
peptide conjugated SPIOs.  
Quantitative image analysis indicates that the LCA over RCA ratio is about 4 fold 
higher when targeted SPIOs were used in carotid ligation mode, as shown in Figure 1. 
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Our results clearly indicate that the 
64
Cu-VINP-SPIOs can be used to image inflammation 
with PET with high specificity and sensitivity. Both fluorescence imaging and MRI were 
also performed with carotid ligated mice and the results confirmed the PET imaging 
result. 
A potential challenge with the use of this nanoparticle is the increase in false 
positive. Since VCAM1 can be overexpressed due to inflammation, the nanoparticles 
targeted with VINP could detect any type of inflammation not just the ones leading to 
plaque development. Therefore, there is a need to find an ideal target that is specific to 
plaque. Inflammatory makers such as hs-CRP, interleukins 6, 10 and 18, soluble CD40 
ligand, P- and E-selectin, NT-proBNP, fibrinogen and cystatin C have shown limited 
success when used by themselves. But the combination of fibrinogen and NT-proBNP 
contained predictive information in addition to clinical parameters. In the future we 
suggest to target multiple markers to provide clinicians with predictive information [44]. 
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IN VIVO TUMOR IMAGING 
Cancer is responsible for one-fourth of deaths in the United States. In 2014, it is 
expected that 1,665,540 people will develop cancer in the United States alone. Of these 
new cases, 235,030 individuals are expected to develop breast cancer [27]. Breast cancer 
growth and metastasis, like other tumors, both depend on the tumor’s capability to 
rapidly form new blood vessels through angiogenesis [2,3].This process begins early in 
tumor development, with tumors smaller than 0.2 mm already showing the presence of 
angiogenesis [20]. As a tumor grows, oxygen and other necessary nutrients become 
scarce due to their limited diffusive nature. Tumor cells are forced to adapt to a hypoxic 
environment. In this environment, there is an upregulation of hypoxia inducible factor-1 
(HIF-1) which signals cell survival by promoting angiogenesis, thus signaling the 
production of angiogenic factors such as vascular endothelial growth factor (VEGF), 
fibroblast growth factor (FGF), and endoglin (CD105) [21]. Tumor imaging with many 
types imaging modalities has been widely studied, however, the most sensitive imaging 
modality is PET imaging compared to existing non invasive diagnostic imaging 
modalities such as US, MR and CT [22]. Because of its superior sensitivity, PET imaging 
is now the standard procedure for cancer diagnosis [23]. However, there are limitations 
with 
18
FDG PET imaging for cancer diagnosis: Low level of 
18
FDG avidity in some 
malignancies such as primary adenocarcinoma of the lung that manifests as a subsolid 
nodule and in primary carcinoid tumors of the lung can lead to misinterpretation of PET 
studies and altered diagnosis. To overcome the potential limitations of 
18
FDG-PET in the 
56 
 
diagnosis, there is a need for the development of PET imaging agents to interrogate 
different metabolic pathways, receptors or targets [8-9].  
In vivo imaging of 4T1 Tumor 
 
Developing therapeutic approaches are focusing on antiangiogenic treatments that 
use vascular targeting to selectively inhibit or destroy the tumor vasculature while 
maintaining normal blood flow in healthy tissue [2,3-10]. Nanoparticle-based molecular 
imaging is also focusing on angiogenic biomarkers because targeting the tumor 
vasculature reduces the needed blood circulation half-life of the nanoparticles and thus 
decreases background signal [27]. Additional benefits of vascular targeting for both 
imaging and therapy include easy access to target cells, low risk of antigen-negative cells, 
no requirement of extravasation, and universal targets for numerous solid tumors [10-12]. 
While no tumor vasculature-specific marker has been found, targets for therapeutic and 
diagnostic applications are emerging based on the unique characteristics of the tumor 
vasculature [18]. Tumor endothelial cells undergo hypoxic stress and rapid proliferation, 
which results in the up-regulation of some proteins that may be used as targets [29]. 
Vascular targeting shows promise for improving diagnostics and therapeutics for many 
solid tumors [2,10,12]. By studying the factors for tumor growth and the characteristics 
of the tumor environment, possible vascular targets have been found from up-regulated 
proteins [10-13]. 
Several VEGF targeting drugs have been approved for cancer treatment 
0
. By 
2007, three direct inhibitors of VEGF were approved for therapy. However, the 
treatments have not shown increased survival rates in all patients. It is possible that 
disease progression may be continuing along different angiogenic pathways even after 
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anti-VEGF therapy, which justifies the need to further explore other vascular targets for 
tumor therapy and diagnostics 
25
. 
CD105, or endoglin, is a transmembrane glycoprotein overexpressed in 
endothelial cells undergoing angiogenesis and up-regulated by hypoxia [3,16,17]. The 
expression level of CD105 correlates with poor prognosis in more than ten different solid 
tumor types,  making it a promising universal target for solid tumor prognostic, 
diagnostic, and therapeutic applications [12,18,20]. Since CD105 is not detectable in 
resting endothelial cells, it is a prime vascular target for antiangiogenic diagnostics [28]. 
Currently, immunohistochemistry of CD105 is a standard approach for determining 
tumor microvessel density [30].  Research studies of nanoparticles conjugated to anti-
CD105 antibodies seek to use CD105 as a target for future drug delivery and imaging 
applications [22]. Previously, both graphene and mesoporous silica cores were 
conjugated to an anti-CD105 antibody. With both core types, in vitro experiments 
showed that CD105 served as an effective vascular target for angiogenic endothelial 
cells. For in vivo studies, a mouse 4T1 tumor model was used. The 4T1 tumor model can 
metastasize similar to human breast cancer and thus accurately represents the late stages 
of cancer [12,18,21]. In mice with 4T1 breast cancer tumors, 
64
Cu labelled nanoparticles 
conjugated to anti-CD105 antibodies demonstrated CD105-specific tumor uptake. PET 
scans of the mice confirmed the increased tumor uptake for both graphene and 
mesoporous silica cores when CD105 targeting was added.[12, 18] Imaging studies have 
sought to create CD105-specific agents for PET and NIRF. Initial in vitro studies showed 
that labeling anti-CD105 antibodies with NIRF dye and 
64
Cu did not affect the antibody 
binding affinity. Serial in vivo PET/NIRF images showed that image contrast and 4T1 
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tumor uptake with CD105 targeting were superior than the contrast and uptake seen in 
passive targeting [30]. In another study, liposomes conjugated to anti-CD105 antibodies 
also helped to enhanced MR imaging [22]. Some anti-CD105 antibodies have already 
moved into clinical trials. TRC105, a monoclonal antibody that binds to CD105, 
underwent its first-in-human clinical trial beginning in January 2008 and has completed 
five clinical studies. TRC105 is well-tolerated at clinically relevant doses and may be 
combined with VEGF inhibitors [20]. 
Currently, the most commonly used technique for cancer detection is X-ray 
imaging to detect abnormal masses or microcalcifications in the body; however, further 
invasive endoscopic catheter-based scans and biopsies need to be conducted in order to 
confirm the presence of a benign or malignant tumor, as well as determine its staging 
[24]. Due to the limited data assessment capabilities of current diagnostics and the 
invasiveness of these procedures, a novel, noninvasive imaging technique needs to be 
developed that will provide physicians with a complete prognosis of the developing 
tumor as well as allow tracking of the tumor overtime. 
In recent years, investigation into new multimodal nanoparticles and imaging 
techniques has begun. Theranostic nanoparticles, which use the same nanoparticles for 
imaging and therapeutic delivery, have been explored. Combining therapy and imaging 
increases cost and synthesis complexity [25]. However, CD105 could be used as a 
theranostic target due to the promise of vascular targeting in imaging applications and 
antiangiogenic therapy. Shifting to imaging modalities, multimodal imaging techniques 
such as PET/CT have been used successfully in clinical applications since the 1990’s 
[26]. PET imaging is highly sensitive and quantitative but has low spatial resolution [27]. 
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CT provides the anatomical context for the PET scan. However, MRI may serve as a 
better anatomic imaging modality than CT especially in soft tissues. A PET/MRI 
combination would allow for an anatomic MR context, functional MR measurement, and 
PET molecular imaging of tumors [26]. MRI is also advantageous over CT because it 
uses no ionizing radiation and has superior soft tissue contrast [28]. Nanoparticles are 
useful as imaging probes because of their physicochemical properties, small size, lack of 
toxicity, ease of functionalization, and high surface area to volume ratio [29]. In 
particular, superparamagnetic iron oxide nanoparticles (SPIOs) have shown promise as 
an MR contrast agent in the past because the SPIOs create a strong localized magnetic 
field disturbance that causes strong negative contrast [28]. Functionalizing SPIOs with 
targeting moieties for specific cellular markers aids in highlighting disease sites [30]. For 
example, αvβ3 integrin–targeted ultrasmall SPIOs decreased T2 relaxivity and increased 
negative contrast of tumors more effectively than plain particles [31]. SPIOs 
radiolabelled with 
64
Cu, a positron-emitting radionuclide, produced strong MR and PET 
signals and showed high blood retention at early time points post-injection [28]. Despite 
the promising results from initial CD105 targeting experimentation using 
64
Cu labeled 
nanoparticles, few studies have been conducted with CD105 as a target. Radiolabeled 
nanoparticles conjugated to anti-CD105 antibodies can further enhance diagnostic and 
prognostic imaging for tumors by highlighting the tumor vasculature, as well as provide a 
universal contrast agent. The development of an agent targeting CD105 that can be used 
in PET/MR multimodal imaging would allow for significantly improved diagnostics. 
This study focuses on the in vitro cellular uptake and in vivo molecular imaging of anti-
CD105 antibodies conjugated to SPIOs. Herein, we report the synthesis and application 
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of a uniform CD105 targeted MRI/PET contrast agent against the in vitro and in vivo 
growth of 4T1 tumor cell line.  
Surface coating and functionalizing 
64
Cu-CD105 Targeted SPIOs 
 






tetraazacyclotetradecane-N,N′,N′′,N′′′-tetraacetic acid (BAT), was conjugated with an 
artificial lipid to form a BAT-PEG-lipid. The SPIOs were made water soluble via a dual 
solvent exchange method. Initially, 6 nm and 14 nm SPIOs and a PEG solution of 88% 
DSPE-PEG(2000)Methoxy (10mg/mL), 2% BAT-PEG-lipid, and 10% DSPE-
PEG(2000)Carboxy (5mg/mL) were mixed at varying weight ratio (1:8 for 6nm and 1:4 
for 14nm). Chloroform was added at 4 times the volume of SPIOs minus the volumes of 
DSPE-PEG(2000). Finally, DMSO was gradually added at 4 times the total volume of the 
contents of the flask. The mixture was left to react for 1 hour before evaporating 20% of 
the DMSO via a vacuum pump. All the flasks were oven-dried overnight and washed 
with chloroform three times before use. All experiments were conducted in a dry box 
(104.7ppm O2, 7.5ppm H2O, and 4.4mbar pressure). 
After the first solvent exchange, the SPIOs were made water soluble by gradually 
mixing the SPIO solution with water at a 1:5 volume ratio. The solution was filtered to 
remove the empty micelles via 3 rounds of centrifuge (100K Da cutoff size filters) at 
25,000 rcf for 20 minutes and 3 rounds of ultracentrifuge at 80,000 rcf for 50 minutes 
(6nm) and 65,000 rcf for 50 minutes (14nm), both at 4˚C. The SPIOs were then filtered 






The hydrodynamic diameter of the BAT-SPIOs and BAT-CD105-SPIOs was 
determined via dynamic light scattering (DLS) (Malvern Instruments Zetasizer Nano ZS, 
UK). The SPIO solution was diluted with Millipore water (mH2O) and size distribution 
data was collected at 25 
o
C for 30 minutes.  
Surface potential of nanoparticle solutions was measured using Malvern 
Instruments Zetasizer Nano ZS, UK. Samples were measured in triplicate at 25 
o
C. Iron 












Figure 23 shows the DLS diameter after step-by-step surface modification. The 
addition of DSPE-PEG coating increases the size to about 38 nm and further conjugation 
of the antibody increased the final size to 52 nm. 
 
In vitro studies with CD105 Targeted SPIOs 
In vitro cell binding assays were employed to evaluate the CD105 targeting of 
CD105 conjugated SPIOs. HUVECs known to express high levels of endoglin were 
incubated for 1 hr at 37 
o
C with 50 ug/ml of DiI labeled CD105-SPIOs or Non-targeted 
SPIOs. 
HUVECs were seeded at 2x10
4
 cells per well in T25 plates 2-3 days prior to 
incubation and grown in medium supplemented with 1-% fetal bovine serum (FBS) and 
antibiotics (penicillin/streptomycin). After incubation for 1 h at 37°C and 5% CO2, cells 
were fixed for 15 min at room temperature using 4% paraformaldehyde in PBS. Nucleus 































images were acquired using a Zeiss LSM microscope with a 40X water-immersion 
objective.  
Binding of CD105-SPIOs to HUVECs was observed, while no significant binding 
of non-targeted SPIOs occurred (Figure 24). Binding of CD105-SPIOs to HUVECs was 
blocked by the addition of 5 uM of CD105 antibody to the media during incubation. 
 
CD105-SPIOs were also incubated with MCF7 cells and imaged following subsequent 
washing. Incubating CD105-SPIOs with MCF-7 cells (CD105 negative) only showed 
background fluorescence level. Overall these results show that DiI labeled CD105-SPIOs 
exhibit strong and specific binding to CD105 positive cells. This is important in moving 
forward with further in vivo investigation of CD105-SPIOs. 
 
 
Figure 26: In vitro investigation of SPIOs in CD105 positive HUVECs using confocal 







MRI and PET imaging capability of 
64
Cu-CD105-SPIOs were evaluated using 
them same MRI and PET systems used for in vivo imaging of tumor. A nanoparticle 
imaging phantom was prepared and used in T2 weighted MR scan. As shown in Figure 
26, a change in contrast is observed with the change in iron concentration from 10 to 100 
μgFe/mL. The PET image shows the corresponding concentration dependent signal 
intensity. The detection threshold for 
64
Cu-CD105-SPIOs was determined to be 10 





Figure 27: In vitro investigation of SPIOs in CD105 negative cells using 









Cu labeling, the SPIO sample was subjected to both radioTLC and 
radioFPLC analysis. The yield was about 76% before purification. Four rounds of filter 
centrifugation were performed to remove the free 
64
Cu-EDTA resulting in RPC of 96% 













Figure 29: RadioTLC analysis of crude sample of 
64




4T1 Tumor Model 
 
There are several reasons that the 4T1 tumor was selected as a suitable 
experimental animal model. First, the tumor cell line that is highly tumorigenic and 
invasive are easily transplanted into the mammary gland so that the primary in the correct 
anatomical site. Second, the progressive spread of the 4T1 metastases to the lymph nodes 
and other organs is very similar to that of human mammary cancer. Also, the 4T1 
metastatic disease develops spontaneously from the primary tumor 
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. 
All animal studies were conducted under a protocol approved by Emory 
University Institutional Animal Care and Use Committee. Female BALB/c mice that 
were 4-5 weeks old were purchased from Harlan (Indianapolis, IN, USA). The 4T1 
model was developed by subcutaneously injecting 2 x 104 cells suspended in 100 uL of 
cells suspended in PBS into the front flank of mice. The tumor size was monitored every 
day and the animals were subjected to in vivo experiments when the tumor diameter 










PET Imaging and Biodistribution studies of CD105 Targeted SPIOs 
 
The PET/CT scans at various time points post injection were performed using a 
microPET/microCT scanner (Inveon rodent model, Siemens Medical Solutions USA, 
Inc.). Image reconstruction, and ROI analysis of the PET data were performed using 
AsiPro software. Tumor bearing mice were each injected a 0.1mgFe/kg dose (50 uCi) of 
64
Cu-CD105-SPIOs (n=3) or 
64
Cu-SPIOs (n=3) via retro orbital before serial PET scans.  
After the PET scan at 24 hr post injection, biodistribution studies were carried to obtain 
the %ID/g values in tumor and other major organs. In each group (targeted and non-
targeted) 3 mice were euthanized, blood, 4T1 tumors and major organs and tissues were 
collected and weighed. The radioactivity in the tissue was measured using a gamma-





Figure 31: Representative microPET/microCT images of 4T1 tumor 1 hr post injection of 
64
Cu-






As shown in Figure 29, only targeted SPIOs produced PET signal in 4T1 tumor. 
The non-targeted SPIOs did not produce a PET signal. Biodistribution was performed 24 







Cu-SPIOs revealed that significant 
RES uptake as previously observed in C57 mice. Blood activity was significantly 
decreased 24 hrs post injection and the tumor uptake showed a slightly higher uptake 
when targeted SPIOs were injected. The mice used in this study, had a very small tumors 
(~5mm x 1mm). 
64
Cu-CD105-SPIOs showed significantly higher tumor to tissue ratio 
compared to non-targeted SPIOs. Specifically, the tissues surrounding the tumor site such 





Figure 32: Biodistribution of 
64
Cu-CD105-SPIOs and non-targeted 
64
Cu-SPIOs 24 hr post 































To further allow the nanoparticles to accumulate in the tumor, two BALB/C mice 
were kept alive post MR imaging. These mice were injected a 0.1mgFe/kg dose of 
CD105-SPIOs. After one day they were re-injected a 150 uCi of 
64
Cu-CD105-SPIOs  
(n=2) via retro orbital. PET imaging was performed 24 hr post injection. The results are 
shown in Figure 31. 
 
As it is indicated in Figure 31, the nanoparticles produced a detectable signal in 
both tumors. In this study the tumors were significantly larger with a diameter of about 
10mm. The imaging time (24 hr post injection) produced images with much lower 
background especially in the liver and spleen areas. The tumor vasculature was clearly 





Figure 33: Representative microPET/microCT images of 4T1 tumor 24hr post injection of 
64










To examine the MR imaging potential and targeting efficiency of 
64
Cu-CD105-
SPIOs, cold particles were injected to 4T1 tumor bearing mice. Animals were scanned 
using a multi slice multi echo sequence to obtain T2 weighted tumor images. The images 
were obtained with fat suppression from 3 Tesla MR scanner (Tim/Trio, Siemens, 
Erlangen, Germany, TR/TE=3600/86 ms, Slice thickness=1 mm, FOV=84X120, 3 
averages, total scan time=183ms). Tumor bearing mice were imaged pre-injection of 
nanoparticles.  
A single dose of CD105-SPIOs (n=3) or non-targeted SPIOs (n=3) were then 
injected (0.1mgFe/kg) via tail vein injection and animals were imaged at 24 hr post 
injection. T2 weighted images of tumors after injection show a negative contrast 
enhancement compared to pre injection images as shown in Figure 32. Analysis of the 
corresponding multi echo T2 maps showed that the decrease in the mean tumor T2 post 
injection of SPIOs. The decrease in the mean tumor T2 produced by CD105 targeted 







Discussion and Conclusion 
 
To achieve sufficient in vivo stability and tumor targeting it is important to 
modify the surface of the SPIOs. This is achieved by the simplified reaction scheme of 
coating the Fe3O4 cores with DSPE-PEG2k-carboxy and PEG-lipid-BAT. Conjugation of 
CD105 antibody using EDAC was then performed before radiolabeling. The reaction was 
performed overnight at 4
o
C. In this synthetic scheme surface PEGylation was perfomed 
once with the incorporation of PEG-caroboxy and PEG-lipid-BAT. This method 
significantly improved the radiolabeling yield and eliminated one post conjugation step. 
We then performed comprehensive characterizations of size and surface charge with 
DLS, TEM and zeta potential to ensure successful surface modification. The final SPIO 
solution was well-dispersed in PBS with no aggregation.  
Serum stability studies confirmed that more than 90% of radioactivity is bound to 
the nanoparticle after 24 hr which ensured that the signal observed in PET studies reflects 
 
 









the distribution of 
64
Cu labeled SPIOs. We then performed quantitative biodistribution 
with 
64
Cu-CD105-SPIOs and non-targeted 
64
Cu-SPIOs. The results were plotted as tumor 
to tissue ratios and showed that the CD105 targeted SPIOs had significantly higher tumor 
to tissue ratios for muscle, fat and blood. These results were consistent with PET imaging 
results for the 5 days post injection 4T1 model where we could only see the small tumor 
with the targeted SPIOs. In this case, the tumor reached a size of about 5 mm x 1 mm 
after 5 days and PET imaging was performed for 60 min right after injection. Longer wait 
time between injection and imaging could have improved the uptake in the tumor since 
nanoparticles have a blood circulation half-life about 35 min. Biodistribution was 
performed by sacrificing the mice 24 hrs post injection, and we found that about 4.2% 





Cu-SPIOs had about 3.2% injection dose per gram in the tumor after 24 hrs. 
Active targeting mediated by affinity ligands may complement EPR (enhanced 
permeability and retention) or provide an alternative delivery mechanism. SPIO 
nanoparticles with their multivanlency can help overcome the weak affinity of some 
ligand antigen pairs. As shown in this work, the addition of CD105 antibody can increase 
the tumor uptake by 50%. This increase in uptake is mainly due to the uptake by tumor 
neuvasculature endothelial cells overexpressing endoglin. This is the first report of 
PET/MR imaging with dual modality 
64
Cu-CD105-SPIOs targeted to endoglin. As shown 
through in vitro and in vivo experiments 
64
Cu-CD105-SPIOs exhibited stability and target 
specificity. The significant finding was the high contrast of SPIOs on the clinical 3 Tesla 
MR scanner. An approximately 50% increase in tumor uptake was observed when using 
active targeting compared to passive targeting based only on EPR effect. By taking 
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advantage of MR soft tissue contrast and PET sensitivity, dual modality SPIOs have a 
great potential in early stage detection of breast cancer tumors. To further evaluate the 
potential of CD105-SPIOs it may be necessary to continue the dual PET/MR imaging 
studies with multiple injection of cold and hot nanoparticles. IHC studies on tumor and 
muscle tissues are also required to quantify the amount of CD105 expression. Also, PCR 
studies are recommended to correlate the expression level of endoglin with the uptake of 
targeted SPIOs. 
Endoglin maybe overexpressed on the neuvasculature endothelial cells in other 
diseases such as atherosclerotic plaque. This could potentially cause problems with 
increasing false positives. 
Radiolabeled nanoparticles conjugated to anti-CD105 antibodies can further 
enhance diagnostic and prognostic imaging for tumors by highlighting the tumor 
vasculature, as well as provide a universal contrast agent. The development of 
64
Cu-
SPIOs targeting CD105 that can be used in PET/MR multimodal imaging would allow 
for significantly improved diagnostics. Although these studies focused on the in vitro 
cellular uptake and in vivo molecular imaging of anti-CD105 antibodies conjugated to 
SPIOs, one class of this antibody (TRC105) is currently in phase II clinical trial for 
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CONCLUSIONS AND FUTURE DIRECTIONS 
 The combination of PET, CT and MRI offers opportunities beyond the use of 
single imaging modality. The synergistic effects of high sensitivity imaging of PET with 
high resolution soft tissue imaging of MRI can lead to easier and improved diagnosis. 
The dual modality contrast agent provides a platform for PET/MR contrast agents which 
can also be targeted. We report the development, in vitro and in vivo imaging of plaque 
and tumor using a novel targeted PET/MR nanoparticle. The core of the nanoparticles is 
made of Fe3O4 which is superparamagnetic due to its size being less than 20 nm. High 
resolution MRI imaging can be performed with high sensitivity when using these SPIOs. 
In addition, radioisotope 
64
Cu was labeled on the surface of the PEG coating to perform 
PET imaging. Although, 
64
Cu has a half-life of about 12.7 hrs, there are other 
radioisoptopes with shorter half-lives that could have been used. Fluorine-18 is one such 
isotope with a half-life of 109 minutes, it has the ideal properties for labeling SPIOs. The 
high percentage (39%) of beta decays by 
64
Cu raises a concern regarding potential 
toxicity. Therefore, 
18
F is a great alternative since it decays by positron emission 97% of 
the time.  
 There are several chelators with high affinity for 
64
Cu such as DOTA, NOTA, and 
TETA. Initially, we observed that DOTA conjugation via the NHS, amine reaction causes 
the aggregation of the nanoparticles before the reaction is complete. This was mainly due 
to the low pH of the DOTA-NHS solution dissolved in water. We learned that dissolving 
the SPIOs at a concentration of 1 mg/ml (1 ml) in phosphate buffer at pH 7.4 before drop 
wise addition of the DOTA-NHS is the key in preventing the aggregation. However, the 
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low radio labeling yield of only 50% was an area we could improve upon. The alternative 
was to pre-conjugate and purify PEG to the chelator and use it during coating. Lipid-
PEG-BAT was already synthesized and used in imaging liposomes and was sent to us 
from Dr. Ferrara’s laboratory at UC Davis. BAT is a derivative of TETA which has 
higher affinity for 
64
Cu compared to DOTA. Using only 2% lipid-PEG-BAT, we reached 
95% radiolabeling yield and a method for the addition of targeting ligand. This simplified 
method was used in developing both tumor targeting and VCAM1 targeting of 
inflammation. 
64
Cu-VINP-SPIOs showed great potential in imaging VCAM1 overexpression in 
the carotid ligation model of inflammation. Although additional studies maybe required 
to confirm the specificity of targeting, the in vivo results with scramble version of the 
peptide served as a decent control. In this case, the ratio of LCA to RCA SUV uptake 
showed was higher when using targeted SPIOs compared to scramble and non-targeted 
SPIOs. Blocking studies with the pre injection of VCAM antibody alone can be 
beneficial in providing further evidence that the targeting is specific. To further evaluate 
the targeting specificity of the VINP-SPIOs, it is important to perform 
immunohistochemistry studies to confirm the expression of VCAM1 in the ligation area. 
Fluorescence microscopy may also be used with the DiI labeled SPIOs to study the 
colocalization of the SPIOs with different types of cells. In our initial studies we found 
that SPIOs get internalized into endothelial cells as well as smooth muscle cells. The 
information from PET/CT imaging can help determine the AHA lesion stage. If there is 
VCAM1 overexpression, VINP-SPIOs will indicate their presence corresponding to AHA 
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lesion 1. Although this information can be useful in identifying the lesion, it can fully 
evaluate the severity of disease.  
Although we have an estimate on the number of CD105 antibodies per particle 
based on the initial amount of PEG-maleimide, it is recommended that the supernatant be 
tested before and after conjugation of the antibody to precisely quantify this number.  
In the three aims of this thesis, the field of PET MR molecular imaging has been 
advanced by the development of protocols for the synthesis and coating of dual modality 
SPIO nanoparticles which are both radiolabeled and targeted to a specific antigen. This 
simplified synthetic scheme allows for development of imaging agents for early stage 
detection of inflammation. In addition, this nanoparticle can be used for multi modal, 
PET/MR imaging of tumor microvasculature. We have shown that targeted 
64
Cu SPIOs 
are a versatile system that combines the advantages of MR and PET contrast agents. 
Because of their potential we studied their in vivo biodistribtion following interavenous 
injection. Experimental results revealed that SPIOs have an ability to provide contrast on 
a clinical 3 Tesla MR scanner in addition to producing high signal intensity in pre-clinical 
PET system. These features make the SPIOs an ideal candidate to be transferred to clinic 
for clinical diagnosis of diseases such as inflammation and cancer.  
 
To publicize these advancements we are planning to publish our work in the 
following research articles: 
 
Masoodzadehgan N, Seo W, Virani N, Gray S, Weiss D, Seo J, Goodman M, Taylor B, 
Ferrara K, Bao G. 2014. “Multi modal plaque imaging with VCAM targeted 
64
Cu-SPIOs”  




Masoodzadehgan N, Gray S, Bao G. 2014. “Nanoparticle Size Review”  
In the submission process. 
 
Masoodzadehgan N, Seo W, Virani N, Gray S, Weiss D, Seo J, Goodman M, Taylor B, 
Ferrara K, Bao G. 2014. “PET-MR imaging of  tumor CD105 expression using targeted 
64
Cu –SPIOs” 
Manuscript in preparation. 
 
 
Several conference posters and presentations created collaborations with colleagues 
in cardiology, imaging, and radiochemistry. To further explore plaque imaging, we are 
currently synthesizing 
64
Cu-VINP-SPIOs to perform biodistirbution and PET/MR 
imaging studies in a rabbit ligation model. The amount of nanoparticles produced needs 
to be scaled up to perform these studies. Each rabbit weights about 2 kg and that is 100 
times the weight of the mice used in our previous imaging studies.  
We have also developed a collaboration with Dr. Hui Mao’s laboratory at Emory 
University. We are planning to continue this collaboration to further understand the effect 
of targeting on PET/MR imaging of 4T1 tumor. Taking advantage of the 3 Tesla MR 
system at Wesley Woods, we can analyze the effect of targeting on imaging breast cancer 
tumors. This scanner is currently used for clinical scans and it can provide valuable 








(BAT), was conjugated with an artificial lipid to form a BAT-PEG-lipid coating using 
Fmoc solid phase synthesis. The synthesis was conducted following methods from 
Katherine W. Ferrara’s laboratory at the University of California, Davis. Initially, Fmoc-
Cys(Mnt)-OH, Fmoc-NH-(PEG)27-COOH, Fmoc-Lys(Fmoc)-OH, and stearic acid were 
serially added to PAL-PEG-PS resin. Next, the protective Mnt group was removed with 
1% TFA/DCM. The unprotected resin was then coupled with the BAT in a 
DMF/DMSO/H2O (1:1:1 v/v/v) solvent, pH of 8. The pH was adjusted with DIPEA, and 
the reaction was monitored with DTNP solution. The resulting product was cleaved by a 
TFA/TIPS/H2O solvent (9.5:2.5:2.5 v/v/v). After cleaving, the product was purified via 
reversed-phase high performance liquid chromatography (HPLC) and the mass was 
confirmed via matrix-assisted laser desorption/ionization (MALDI). 
 
Iron measurement via Ferrozine Assay. The iron content of the SPIOs was determined 
by mixing 50 µL of dilute SPIO solution with 50 µL of 12M HCl for 30 minutes at room 
temperature on a shaker. Next, the solution was mixed with 240 µL of 2M NaOH, 50 µL 
of 4N ammonium acetate, and 110 µL of 5% hydroxylamine HCl for 30 minutes. After 
incubation, 50 µL of sample was mixed with 50 µL of 0.1% ferrozine solution and 
incubated for 15 minutes. Absorbance was read at 562 nm with 810 nm as reference. 
 
Characterization via Transmission Electron Microscopy (TEM). 
64
Cu-VINP-SPIO 
were analyzed after three weeks post radiolabeling. A 5 µl sample suspension of both 
6nm and 14nm SPIOs were place on a 400 mesh carbon coated copper grid that had been 
made hydrophilic by glow discharge.  After 5 minutes, grid with the sample was dragged 
by the side of grid on a piece of filter paper.  For negative staining, 5 µl of 1% aqueous 
methylamine tungstate (MAT) or phosphotungstic acid (PTA) was applied onto grid 
immediately after sample removal, and then removed as described above after 30 



















Table1: Organ biodistribution of 6nm 
64
Cu-SPIOs (control) as % injected dose per gram 
tissue. 
  
Table2: Organ biodistribution of 6nm 
64
Cu-VINP-SPIOs (targeted) as % injected dose 
per gram tissue. 
15 min pi blood heart lung liver spleen kidney muscle brain bone fat 
avg  26.57% 3.21% 5.93% 8.81% 3.96% 26.35% 0.91% 0.47% 1.41% 1.04% 
std dev 0.80% 0.53% 0.85% 1.28% 0.32% 2.09% 0.13% 0.07% 0.15% 0.25% 
1 hr pi 
         
  
avg  10.26% 1.83% 4.14% 18.65% 15.62% 21.14% 0.56% 0.31% 1.57% 0.80% 
std dev 0.04% 0.40% 1.06% 4.47% 4.95% 2.88% 0.07% 0.07% 0.32% 0.19% 
3 hr pi 
         
  
avg  4.88% 1.64% 4.47% 17.61% 9.35% 10.12% 0.69% 0.22% 1.39% 0.66% 
std dev 0.32% 0.24% 0.59% 2.25% 2.24% 1.64% 0.21% 0.04% 0.37% 0.19% 
24 hr pi 
         
  
avg  2.20% 1.64% 3.95% 11.25% 4.25% 6.20% 0.44% 0.26% 0.88% 0.60% 





15 min pi blood heart lung liver spleen kidney muscle brain bone fat 
avg  44.22% 5.07% 6.54% 5.51% 11.47% 8.65% 0.74% 0.73% 1.65% 0.72% 
std dev 7.65% 1.09% 1.34% 1.08% 2.88% 1.67% 0.13% 0.16% 0.45% 0.13% 
1 hr  pi 
         
  
avg  26.25% 3.10% 4.76% 19.62% 13.35% 6.53% 0.52% 0.55% 2.25% 0.66% 
std dev 2.94% 0.60% 0.55% 3.14% 0.43% 0.85% 0.07% 0.09% 0.42% 0.34% 
3 hr pi 
         
  
avg  21.81% 2.62% 3.30% 25.16% 16.34% 5.55% 0.50% 0.48% 1.58% 0.58% 
std dev 1.53% 0.28% 1.04% 3.38% 4.27% 1.02% 0.07% 0.04% 0.80% 0.05% 
24 hr pi 
         
  
avg  6.33% 1.66% 2.56% 10.04% 9.96% 3.63% 0.36% 0.21% 1.18% 0.44% 





Table3: Organ biodistribution of 14nm 
64




Table4: Organ biodistribution of 14nm 
64
Cu-VINP-SPIOs (targeted) as % injected dose 







15 min pi blood heart lung liver spleen kidney muscle brain bone fat 
avg  38.38% 5.96% 9.01% 9.29% 7.23% 6.78% 0.67% 1.02% 1.87% 0.99% 
std dev 3.44% 1.55% 0.62% 1.62% 1.64% 0.68% 0.02% 0.24% 0.35% 0.23% 
1 hr  pi 
         
  
avg  22.89% 3.09% 6.11% 18.30% 23.76% 5.88% 0.55% 0.58% 1.78% 0.77% 
std dev 4.63% 0.50% 1.64% 2.61% 2.77% 0.67% 0.09% 0.12% 0.46% 0.12% 
3 hr pi 
         
  
avg  16.75% 2.97% 5.81% 35.32% 38.12% 5.65% 0.49% 0.40% 2.30% 0.86% 
std dev 3.68% 0.43% 1.28% 6.79% 8.49% 1.14% 0.06% 0.06% 0.56% 0.16% 
24 hr pi 
         
  
avg  1.01% 1.00% 2.17% 9.25% 14.14% 2.29% 0.21% 0.10% 0.99% 0.32% 
std dev 0.18% 0.06% 0.19% 0.26% 3.22% 0.10% 0.03% 0.01% 0.10% 0.06% 
15 min pi blood heart lung liver spleen kidney muscle brain bone fat 
avg  16.04% 3.94% 9.27% 20.78% 10.46% 15.08% 0.88% 0.49% 1.86% 0.85% 
std dev 2.08% 0.80% 0.75% 1.91% 0.81% 2.09% 0.14% 0.03% 0.21% 0.11% 
1 hr  pi 
         
  
avg  7.95% 2.74% 7.90% 23.13% 15.87% 8.78% 0.63% 0.37% 1.58% 0.75% 
std dev 0.48% 0.24% 0.56% 2.48% 1.02% 0.80% 0.03% 0.03% 0.12% 0.14% 
3 hr pi 
         
  
avg  5.01% 2.92% 8.93% 26.65% 15.00% 8.99% 0.60% 0.36% 1.79% 0.85% 
std dev 0.57% 0.33% 0.48% 0.66% 1.23% 0.95% 0.04% 0.04% 0.19% 0.12% 
24 hr pi 
         
  
avg  1.20% 2.96% 6.41% 15.16% 7.30% 7.37% 0.59% 0.45% 1.45% 0.64% 
std dev 0.13% 0.25% 0.84% 1.16% 0.82% 0.78% 0.06% 0.06% 0.09% 0.13% 
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Chapter 5: Ex vivo autoradiography of carotid after injection of 50 µCi dose of 
64
Cu-
VINP-SPIOs in the carotid ligation ApoE
-/-
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